Compare ATHM & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | RCUS |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2013 | 2018 |
| Metric | ATHM | RCUS |
|---|---|---|
| Price | $19.87 | $19.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $28.00 | ★ $28.22 |
| AVG Volume (30 Days) | 450.1K | ★ 913.0K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 8.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.09 | $6.79 |
| 52 Week High | $31.40 | $26.40 |
| Indicator | ATHM | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 29.39 | 43.81 |
| Support Level | N/A | $8.86 |
| Resistance Level | $23.60 | $21.55 |
| Average True Range (ATR) | 0.64 | 1.09 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 16.60 | 36.70 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider with 30% market share, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.